Efficacy and Safety of Botulinum Toxin Type A (Botox®)' in Blepharospasm and Hemifacial Spasm

Abstract

lepharospasm (BPS) and hemifacial spasm (HFS) are the most common movement disorders of the craniofacial area. BPS is a focal dystonia characterized by involuntary and forced closure of eyelids due to spasmodic contractions of the orbital and periorbital muscles. The clinical evidence usually starts with involuntary blinks and strong dystonic contractions that may develop in the orbicularis oculi muscles leading to a functional loss of vision. These spasms may spread to nasal, corrugator and ® was diluted by sterile saline to adjust the dose to 5U/0.1 ml before injection. Pretarsal administration was applied. The average dose of Botox ® required for an optimal response was 30-35 MU for BPS, 25-30 MU for HFS. R Re es su ul lt ts s: : The therapeutic effect started after 3 to 5 days, and initial repetitive efficacy intervals (REI) [2nd REI, BPS (13,9 months) and HFS (5,8 months)] were longer than the last mean REI [7th REI, BPS (5.9 months) and HFS (3.7 months)], and there were statistically significant differences between BPS and HFS groups (p<0.05). The treatment was effective in both BPS and HFS. Adverse effects occurred in 7.29% of the injection series. C Co on nc cl lu us si io on n: : BTX-A is established as an effective and safe agent in the treatment of BPS and HFS. The side effects of BTA-X administration may be reduced with the help of injection material used and the application technique.